Brenton L. Saunders is Allergan's New Chairman of the Board

Brenton L. Saunders is Allergan’s new Chairman of the Board, the company reports.

Effective today, Saunders will replace Paul Bisaro, who served as Executive Chairman since July 1, 2014.  Bisaro will remain a member of the Allergan Board of Directors.  In addition to the role of Chairman, Saunders will retain his current role as Chief Executive Officer and President.  Also, effective today, Christopher Coughlin has been elected Lead Independent Director.

Saunders has served as a member of Allergan's Board of Directors and as Chief Executive Officer and President since July 2014. He was previously Chief Executive Officer and President of Forest Laboratories and a member of the Board of Directors of Forest. He is currently a member of the Board of Trustees of the University of Pittsburgh, The Business Council and PhRMA.

Bisaro previously served as President and Chief Executive Officer and as Chairman of Allergan’s Board of Directors beginning October 2013; prior to serving as Chairman he served on the Board of Directors beginning September 2007. Bisaro currently serves on the Boards of Directors of Zimmer Biomet Holdings, Inc. and Zoetis, Inc. and on the Board of Visitors of the Catholic University of America's Columbus School of Law.

Coughlin is replacing Cathy Klema, who has served as our Lead Independent Director since 2014 and will remain a member of the board. Coughlin is currently a member of Allergan's Compensation Committee and the Nominating and Corporate Governance Committee.  In 2015, he was recognized by National Association of Corporate Directors as Director of the Year.  He joined the Allergan board in July 2014 after serving as a member of the Board of Directors of Forest since 2011.  Coughlin currently serves as the Chairman of the Board of Dun & Bradstreet. He also serves on the Board of Directors of Alexion Pharmaceuticals and Hologic, Inc.